Market News

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Research Report To Design A Cohesive And Predictive Business Strategy Till 2025

B-cell Maturation Antigen (BCMA) Targeted Therapies Market
B-cell Maturation Antigen (BCMA) Targeted Therapies Market

Recurrence of multiple myeloma has been a highly prevalent health condition, which requires novel and effective immunotherapeutic treatment. According to Leukemia Research by Elsevier, as of 2014, the incidence of multiple myeloma is estimated to be around 120,000 cases per year, with a global prevalence of over one million cases. B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen targeted therapy for the treatment of multiple myeloma. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs). These advanced therapies are expected to improve the survival rate of multiple myeloma patients.

Download Free PDF Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/190

Market Key Players:

Key players operating in the development of B-cell maturation antigen (BCMA) targeted therapies market are, Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., Autolus Ltd.

Market Dynamics:

Increasing prevalence of multiple myeloma is expected to favor the B-cell maturation antigen (BCMA) targeted therapies market worldwide. According to the American Cancer Society, U.S., in 2016, the lifetime risk for multiple myeloma was around 1 in 143 people, with an estimated 30,280 adults (17,490 men and 12,790 women) diagnosed with multiple myeloma. The mortality rate of the disease was estimated to be 12,590 (6,660 men and 5,930 women) in 2016. Key players are actively involved in the development of immunotherapies targeting BCMA for the treatment of multiple myeloma, the demand for which is expected to increase, This in turn, is expected to boost development of novel treatments for relapsed or refractory myeloma. Furthermore, patients undergoing existing drug therapies are prone to the risk of relapse. Hence, B-cell maturation antigen targeted therapy, which primarily addresses this concern is expected to gain rapid traction.

Increase in number of pipeline products are expected to boost growth of the B-cell maturation Antigen (BCMA) targeted therapies market

Market players are actively investing in research and development of novel multiple myeloma therapies to develop alternatives for existing drugs. These therapies includes chimeric antigen receptor T cells, antibody-drug conjugate, and Bi-specific antibodies. For instance, GlaxoSmithKline Plc. (GSK2857916) is developing the antibody drug conjugate drug with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA. The robust pipeline therapies for treatment of multiple myeloma is expected to boost growth of the B-cell maturation Antigen (BCMA) targeted therapies market

High unmet needs by the recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market

The patients undergoing chemotherapy and radiation therapy are at high risk of recurrence of cancer as they develop resistance to these therapy. At present there are no treatment options are available for patients with recurrent cancer and hence the BCMA targeted therapies provides breakthrough therapeutic options for the treatment of relapsed or refractory multiple myeloma and will also cater to the current unmet needs for the treatment of relapsed or refractory myeloma, where the existing treatment modalities have proved to be clinically inefficient.

Market Taxonomy:

This report segments the global B-cell maturation antigen (BCMA) targeted therapies market on the basis on product type, indication, and regions. On the basis of product type, the market is segmented into antibody drug conjugates, CAR-T cells, bispecific antibodies. On the basis of indication, the market is segmented into acute lymphoblastic leukemia and multiple myeloma. For comprehensive understanding of market dynamics, the global B-cell Maturation Antigen (BCMA) targeted therapies market is analyzed across key geographical regions namely, North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

For any Query, Talk to Analyst @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/190

TechnoBleak Media Inc. (TechnoBleak.com) is an Independent Online News Portal intended to deliver news related to Apps, Technology, Startups, and Gadgets. It is run by writers and co-workers living in different parts of the world. We aim to create high-quality content for our readers who like to read business and technology news & updates. At TechnoBleak, we offer the latest news, breakthroughs, and analysis with emphasis on expert opinion and commentary from the Technology and Startups community.

Office Address:

TechBleak Media Inc.
501 Boylston Street,
Boston, MA 02116.

EMail: [email protected]